| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Bergamini A et al. | Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. | 2016 | Expert Opin Investig Drugs | pmid:27797594 |
| Zhong P et al. | Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy. | 2016 | Biomacromolecules | pmid:27723970 |
| Jerjian TV et al. | Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. | 2016 | Pharmacotherapy | pmid:26799352 |
| Heudi O et al. | Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. | 2016 | J Pharm Biomed Anal | pmid:26771131 |
| de Vries CL et al. | Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. | 2016 | J. Neurooncol. | pmid:26732082 |
| Elsada A et al. | NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. | 2016 | Lancet Oncol. | pmid:26703893 |
| Luo Q et al. | Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. | 2016 | Anal. Chem. | pmid:26629796 |
| Gebhart G et al. | Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. | 2016 | Ann. Oncol. | pmid:26598545 |
| Ponte JF et al. | Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. | 2016 | Neoplasia | pmid:27889646 |
| Hassan R et al. | Mesothelin Immunotherapy for Cancer: Ready for Prime Time? | 2016 | J. Clin. Oncol. | pmid:27863199 |
| Kim SB et al. | Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. | 2016 | Int. J. Cancer | pmid:27428671 |
| Mitsuya K et al. | Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. | 2016 | BMC Cancer | pmid:27377061 |
| Esteva FJ et al. | What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? | 2015 | Am Soc Clin Oncol Educ Book | pmid:25993162 |
| Hamblett KJ et al. | AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. | 2015 | Mol. Cancer Ther. | pmid:25931519 |
| Ab O et al. | IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. | 2015 | Mol. Cancer Ther. | pmid:25904506 |
| Weiler D et al. | Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. | 2015 | J Thorac Oncol | pmid:25789838 |
| Eisenstein M | Medicine: Eyes on the target. | 2015 | Nature | pmid:26580159 |
| Li T et al. | Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. | 2015 | Appl. Biochem. Biotechnol. | pmid:25564203 |
| Carneiro BA et al. | Emerging therapeutic targets in bladder cancer. | 2015 | Cancer Treat. Rev. | pmid:25498841 |
| Mang Y et al. | Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. | 2015 | Int. Immunopharmacol. | pmid:25467246 |